SCOPUS 정보 검색 플랫폼

Volumn 15, Issue 1, 2018, Pages 1-2

The U.S. food and drug administration's experience with ivacaftor in cystic fibrosis: Establishing efficacy using in vitro data in lieu of a clinical trial

(5) Durmowicz, Anthony G a Lim, Robert a Rogers, Hobart a Rosebraugh, Curtis J a Chowdhury, Badrul A a

a CENTER FOR DRUG EVALUATION AND RESEARCH (United States)

Author keywords

CFTR; Chloride channels; Cystic fibrosis; Drug development

Indexed keywords

CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; AMINOPHENOL DERIVATIVE; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT; QUINOLONE DERIVATIVE;

CHLORIDE TRANSPORT; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRUG EFFICACY; EXPERIENCE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; IN VITRO STUDY; NONHUMAN; REVIEW; UNITED STATES; CHEMISTRY; DRUG APPROVAL; DRUG DEVELOPMENT; GENETICS; MUTATION; SWEAT;

AMINOPHENOLS; CHLORIDE CHANNEL AGONISTS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG APPROVAL; DRUG DEVELOPMENT; HUMANS; MUTATION; QUINOLONES; SWEAT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85039797009 PISSN: 23256621 EISSN: None Source Type: Journal
DOI: 10.1513/AnnalsATS.201708-668PS Document Type: Review

Times cited : (102)

References (6)

1
- 77951700065
- U.S. Food and Drug Administration [accessed 2017 Nov 21]
- U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products [accessed 2017 Nov 21]. Available from: https://www. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview. process&ApplNo=203188.
- Drugs@FDA: FDA Approved Drug Products

2
- 84989291045
- The Cystic Fibrosis Foundation patient registry: Design and methods of a national observational disease registry
- Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation patient registry: design and methods of a national observational disease registry. Ann Am Thorac Soc 2016;13:1173-1179.
- (2016) Ann Am Thorac Soc , vol.13 , pp. 1173-1179
- Knapp, E.A.¹ Fink, A.K.² Goss, C.H.³ Sewall, A.⁴ Ostrenga, J.⁵ Dowd, C.⁶

3
- 84873070931
- [accessed 2017 Nov 21]
- Clinical and Functional Translation of CFTR [accessed 2017 Nov 21]. Available from: https://www.cftr2.org/mutations-history.
- Clinical and Functional Translation of CFTR

4
- 0029823833
- Cystic fibrosis
- Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-1256.
- (1996) Am J Respir Crit Care Med , vol.154 , pp. 1229-1256
- Davis, P.B.¹ Drumm, M.² Konstan, M.W.³

5
- 85017465243
- Cystic fibrosis
- Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers 2015;1:15010.
- (2015) Nat Rev Dis Primers , vol.1 , pp. 15010
- Ratjen, F.¹ Bell, S.C.² Rowe, S.M.³ Goss, C.H.⁴ Quittner, A.L.⁵ Bush, A.⁶

6
- 0029866870
- The molecular basis for disease variability in cystic fibrosis
- Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996;4:65-73.
- (1996) Eur J Hum Genet , vol.4 , pp. 65-73
- Kerem, B.¹ Kerem, E.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.